Radioimmunotherapy: A novel treatment of non-Hodgkin lymphoma
90Y-ibritumomab tiuxetan (Zevalin) and 131I-tositumomab (Bexxar) are current choices for radioimmunotherapy (RIT) of patients with follicular rituximab-relapsed or refractory CD20+ follicular B-cell NHL. Bexxar is available in the United States and Canada, while Zevalin was approved for use only in...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Institute of Oncology, Sremska Kamenica, Serbia
2010-01-01
|
| Series: | Archive of Oncology |
| Subjects: | |
| Online Access: | http://www.doiserbia.nb.rs/img/doi/0354-7310/2010/0354-73101002023M.pdf |